anti-TSLP mAb

An anti-TSLP mAb (anti-thymic stromal lymphopoietin monoclonal antibody) is a class of biologic therapies designed to target and neutralize thymic stromal lymphopoietin (TSLP), an epithelial cell-derived alarmin cytokine. TSLP plays a critical upstream role in initiating and perpetuating type 2 (Th2) helper T-cell-mediated inflammatory cascades in response to environmental triggers, allergens, and pathogens at barrier surfaces. By binding to TSLP, these monoclonal antibodies prevent its interaction with the heterodimeric TSLP receptor complex (composed of TSLPR and IL-7Rα), thereby suppressing downstream signaling pathways (such as JAK/STAT and PI3K/Akt) and reducing the production of downstream type 2 cytokines (including IL-4, IL-5, and IL-13). This class of therapeutics, which includes approved agents like tezepelumab and investigational candidates like solrikitug, GB-0895, and QX008N, is primarily developed for the treatment of severe asthma, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis, and other TSLP-driven allergic and inflammatory diseases.

Other names

anti-TSLP antibodyanti-TSLP monoclonal antibodyanti-thymic stromal lymphopoietin monoclonal antibody